Preoperative ctDNA Detects Occult Nodal Metastasis and Predicts Recurrence in Early-Stage Esophageal Squamous Cell Carcinoma
Posted inGeneral Surgery news Oncology Pathology & Lab Medicine

Preoperative ctDNA Detects Occult Nodal Metastasis and Predicts Recurrence in Early-Stage Esophageal Squamous Cell Carcinoma

A multi-center study demonstrates that preoperative ctDNA detection significantly outperforms traditional clinical criteria in predicting nodal upstaging and survival outcomes for patients with clinical stage I/II ESCC, potentially redefining neoadjuvant treatment strategies.
Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer
Posted innews Oncology Otorhinolaryngology Pathology & Lab Medicine

Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer

Research identifies postoperative lymphatic exudate as a superior source of ctDNA for detecting molecular residual disease in HPV-independent head and neck cancer. This proximal liquid biopsy significantly outperforms plasma in predicting locoregional recurrence and may refine adjuvant treatment decisions for intermediate-risk patients.
ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: DYNAMIC-III Validates Prognosis but Questions Intensification
Posted inGastroenterology news Oncology Pathology & Lab Medicine

ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: DYNAMIC-III Validates Prognosis but Questions Intensification

The randomized phase 2/3 DYNAMIC-III trial shows that postoperative circulating tumor DNA (ctDNA) strongly stratifies recurrence risk in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with outcomes close to standard care; escalation for ctDNA-positive disease did not improve recurrence-free survival.
ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial
Posted innews Oncology Pathology & Lab Medicine

ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial

The DYNAMIC-III trial validates circulating tumor DNA (ctDNA) as a strong prognostic marker in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with near-standard outcomes, but escalation for ctDNA-positive patients failed to improve recurrence-free survival.
Early ctDNA Dynamics Predict Long-Term Survival in dMMR/MSI-H Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
Posted inOncology Pathology & Lab Medicine Specialties

Early ctDNA Dynamics Predict Long-Term Survival in dMMR/MSI-H Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors

Change in circulating tumor DNA (ctDNA) one month after treatment initiation predicts progression-free and overall survival in patients with dMMR/MSI-H metastatic colorectal cancer receiving immune checkpoint inhibitors, offering a potential biomarker for therapeutic decision-making.